SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit
SpringWorks Therapeutics (Nasdaq: SWTX) announced its participation in a Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit on May 21, 2021, at 10:00 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SpringWorks Therapeutics (Nasdaq: SWTX) announced its participation in a Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit on May 21, 2021, at 10:00 AM ET. The event aims to highlight the company’s efforts in developing medicines for rare diseases and cancer. Interested parties can access the live webcast through the company’s website, with a replay available afterward. SpringWorks is known for its precision medicine approach and is advancing clinical trials for targeted oncology product candidates.
Details
News Market Reaction – SWTX
The recorded move for SWTX in the trading session of this news was +7.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STAMFORD, Conn., May 14, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit on Friday, May 21st at 10:00AM ET.
To access the live webcast please visit the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the summit.
About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.
Contact:
Kim Diamond
Phone: 203-561-1646
Email: kdiamond@springworkstx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.